A small-molecule antivirulence agent for treating Clostridium difficile infection

Science Translational Medicine

Volumn 7, Issue 306, 2015, Pages

  Bender, Kristina Oresic ^a   Garland, Megan ^a   Ferreyra, Jessica A ^a   Hryckowian, Andrew J ^a   Child, Matthew A ^a   Puri, Aaron W ^a,d   Solow Cordero, David E ^b   Higginbottom, Steven K ^a   Segal, Ehud ^a   Banaei, Niaz ^a   Shen, Aimee ^c   Sonnenburg, Justin L ^a   Bogyo, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYSTEINE PROTEINASE; EBSELEN; GLUCOSYLTRANSFERASE; ANTIINFECTIVE AGENT; ORGANOSELENIUM DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL PROTECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEIN DOMAIN; ANIMAL; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; ISOLATION AND PURIFICATION; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZOLES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; MICE; ORGANOSELENIUM COMPOUNDS; VIRULENCE;

EID: 84942543705     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac9103     Document Type: Article

References (64)

1. C. M. Surawicz, L. J. Brandt, D. G. Binion, A. N. Ananthakrishnan, S. R. Curry, P. H. Gilligan, L. V. McFarland, M. Mellow, B. S. Zuckerbraun, Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498 (2013).
2. Center for Disease Control and Prevention, Antibiotic Resistance Threats in the United States 2013 (CDC, Atlanta, GA, 2013).
3. R. Douglas Scott II, The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, Division of Healthcare Quality Promotion National Center for Preparedness, Detection, and Control of Infectious Diseases. Coordinating Center for Infectious Diseases (CDC, Atlanta, GA, 2009).
4. E. R. Dubberke, M. A. Olsen, Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55, S88-S92 (2012).
5. M.-C. Tran, M. C. Claros, E. J. Goldstein, Therapy of Clostridium difficile infection: Perspectives on a changing paradigm. Expert Opin. Pharmacother. 14, 2375-2386 (2013).
6. F. C. Lessa, Y. Mu, W. M. Bamberg, Z. G. Beldavs, G. K. Dumyati, J. R. Dunn, M. M. Farley, S. M. Holzbauer, J. I. Meek, E. C. Phipps, L. E. Wilson, L. G. Winston, J. A. Cohen, B. M. Limbago, S. K. Fridkin, D. N. Gerding, L. C. McDonald, Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825-834 (2015).
7. C. P. Kelly, Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect. 18, 21-27 (2012).
8. M. Y. Hu, K. Katchar, L. Kyne, S. Maroo, S. Tummala, V. Dreisbach, H. Xu, D. A. Leffler, C. P. Kelly, Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136, 1206-1214 (2009).
9. C. Walsh, Antibiotics: Actions, Origins, Resistance (ASM Press, Washington, DC 2003).
10. C. A. Arias, B. E. Murray, The rise of the Enterococcus: Beyond vancomycin resistance. Nat. Rev. Microbiol. 10, 266-278 (2012).
11. A. M. Ramsey, M. D. Zilberberg, Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000-2006. Infect. Control Hosp. Epidemiol. 30, 184-186 (2009).
12. E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal, W. M. de Vos, C. E. Visser, E. J. Kuijper, J. F. Bartelsman, J. G. Tijssen, P. Speelman, M. G. Dijkgraaf, J. J. Keller, Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013).
13. E. G. Pamer, Fecal microbiota transplantation: Effectiveness, complexities, and lingering concerns. Mucosal Immunol. 7, 210-214 (2014).
14. P. F. Vale, A. Fenton, S. P. Brown, Limiting damage during infection: Lessons from infection tolerance for novel therapeutics. PLOS Biol. 12, e1001769 (2014).
15. Y. Taur, E. G. Pamer, Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat. Med. 20, 246-247 (2014).
16. J. K. Shim, S. Johnson, M. H. Samore, D. Z. Bliss, D. N. Gerding, Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633-636 (1998).
17. L. Kyne, M. Warny, A. Qamar, C. P. Kelly, Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342, 390-397 (2000).
18. J. R. O'Connor, S. Johnson, D. N. Gerding, Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136, 1913-1924 (2009).
19. D. Drudy, N. Harnedy, S. Fanning, M. Hannan, L. Kyne, Emergence and control of fluoroquinoloneresistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect. Control Hosp. Epidemiol. 28, 932-940 (2007).
20. R. N. Pruitt, D. B. Lacy, Toward a structural understanding of Clostridium difficile toxins A and B. Front. Cell. Infect. Microbiol. 2, 28 (2012).
21. A. Shen, P. J. Lupardus, M. M. Gersch, A. W. Puri, V. E. Albrow, K. C. Garcia, M. Bogyo, Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat. Struct. Mol. Biol. 18, 364-371 (2011).
22. N. M. Chumbler, M. A. Farrow, L. A. Lapierre, J. L. Franklin, D. B. Haslam, J. R. Goldenring, D. B. Lacy, Clostridium difficile toxin B causes epithelial cell necrosis through an autoprocessingindependent mechanism. PLOS Pathog. 8, e1003072 (2012).
23. M. A. Farrow, N. M. Chumbler, L. A. Lapierre, J. L. Franklin, S. A. Rutherford, J. R. Goldenring, D. B. Lacy, Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proc. Natl. Acad. Sci. U.S.A. 110, 18674-18679 (2013).
24. Z. Zhang, M. Park, J. Tam, A. Auger, G. L. Beilhartz, D. B. Lacy, R. A. Melnyk, Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore. Proc. Natl. Acad. Sci. U.S.A. 111, 3721-3726 (2014).
25. B. A. Feltis, S. M. Wiesner, A. S. Kim, S. L. Erlandsen, D. L. Lyerly, T. D. Wilkins, C. L. Wells, Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock 14, 629-634 (2000).
26. S. R. Eaton, J. E. Mazuski, Overview of severe Clostridium difficile infection. Crit. Care Clin. 29, 827-839 (2013).
27. J. Pépin, L. Valiquette, B. Cossette, Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173, 1037-1042 (2005).
28. G. J. Babcock, T. J. Broering, H. J. Hernandez, R. B. Mandell, K. Donahue, N. Boatright, A. M. Stack, I. Lowy, R. Graziano, D. Molrine, D. M. Ambrosino, W. D. Thomas Jr., Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74, 6339-6347 (2006).
29. Z. Yang, J. Ramsey, T. Hamza, Y. Zhang, S. Li, H. G. Yfantis, D. Lee, L. Hernandez, W. Seghezzi, J. M. Furneisen, N. M. Davis, A. G. Therien, H. Feng, Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect. Immun. 83, 822-831 (2015).
30. I. Lowy, D. C. Molrine, B. A. Leav, B. M. Blair, R. Baxter, D. N. Gerding, G. Nichol, W. D. Thomas Jr., M. Leney, S. Sloan, C. A. Hay, D. M. Ambrosino, Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205 (2010).
31. S. A. Kuehne, S. T. Cartman, J. T. Heap, M. L. Kelly, A. Cockayne, N. P. Minton, The role of toxin A and toxin B in Clostridium difficile infection. Nature 467, 711-713 (2010).
32. D. Lyras, J. R. O'Connor, P. M. Howarth, S. P. Sambol, G. P. Carter, T. Phumoonna, R. Poon, V. Adams, G. Vedantam, S. Johnson, D. N. Gerding, J. I. Rood, Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179 (2009).
33. J. D. Ballard, Medical microbiology: A toxin contest. Nature 467, 665-666 (2010).
34. S. Janezic, M. Marín, A. Martín, M. Rupnik, A new type of toxin A-negative, toxin B-positive Clostridium difficile strain lacking a complete tcdA gene. J. Clin. Microbiol. 53, 692-695 (2015).
35. B. Elliott, M. M. Squire, S. Thean, B. J. Chang, J. S. Brazier, M. Rupnik, T. V. Riley, New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J. Med. Microbiol. 60, 1108-1111 (2011).
36. R. Maiti, G. H. Van Domselaar, H. Zhang, D. S. Wishart, SuperPose: A simple server for sophisticated structural superposition. Nucleic Acids Res. 32, W590-W594 (2004).
37. M. Egerer, T. Giesemann, T. Jank, K. J. F. Satchell, K. Aktories, Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J. Biol. Chem. 282, 25314-25321 (2007).
38. A. W. Puri, P. J. Lupardus, E. Deu, V. E. Albrow, K. C. Garcia, M. Bogyo, A. Shen, Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem. Biol. 17, 1201-1211 (2010).
39. M. J. Gurwith, C. Langston, B. Dunsmore, Morphologic and functional effects of Clostridium difficile enterotoxin in tissue culture. Can. J. Microbiol. 28, 100-105 (1982).
40. T. Yamaguchi, K. Sano, K. Takakura, I. Saito, Y. Shinohara, T. Asano, H. Yasuhara, Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29, 12-17 (1998).
41. L. Favrot, A. E. Grzegorzewicz, D. H. Lajiness, R. K. Marvin, J. Boucau, D. Isailovic, M. Jackson, D. R. Ronning, Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nat. Commun. 4, 2748 (2013).
42. O. J. Lieberman, M. W. Orr, Y. Wang, V. T. Lee, High-throughput screening using the differential radial capillary action of ligand assay identifies ebselen as an inhibitor of diguanylate cyclases. ACS Chem. Biol. 9, 183-192 (2014).
43. K. P. Bhabak, G. Mugesh, Functional mimics of glutathione peroxidase: Bioinspired synthetic antioxidants. Acc. Chem. Res. 43, 1408-1419 (2010).
44. T. Sakurai, M. Kanayama, T. Shibata, K. Itoh, A. Kobayashi, M. Yamamoto, K. Uchida, Ebselen, a seleno-organic antioxidant, as an electrophile. Chem. Res. Toxicol. 19, 1196-1204 (2006).
45. G. K. Azad, R. S. Tomar, Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways. Mol. Biol. Rep. 41, 4865-4879 (2014).
46. L. Piovan, M. F. M. Alves, L. Juliano, D. Brömme, R. L. O. R. Cunha, L. H. Andrade, Chemoenzymatic synthesis of organoselenium(IV) compounds and their evaluation as cysteine protease inhibitors. J. Braz. Chem. Soc. 21, 2108-2118 (2010).
47. S. Li, L. Shi, Z. Yang, Y. Zhang, G. Perez Cordon, T. Huang, J. Ramsey, N. Oezguen, T. C. Savidge, H. Feng, Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect. Immun. 83, 502-513 (2015).
48. S. Li, L. Shi, Z. Yang, H. Feng, Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog. Dis. 67, 11-18 (2013).
49. J. M. Lanis, L. D. Heinlen, J. A. James, J. D. Ballard, Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLOS Pathog. 9, e1003523 (2013).
50. K. M. Ng, J. A. Ferreyra, S. K. Higginbottom, J. B. Lynch, P. C. Kashyap, S. Gopinath, N. Naidu, B. Choudhury, B. C. Weimer, D. M. Monack, J. L. Sonnenburg, Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502, 96-99 (2013).
51. J. Wst, N. M. Sullivan, U. Hardegger, T. D. Wilkins, Investigation of an outbreak of antibioticassociated colitis by various typing methods. J. Clin. Microbiol. 16, 1096-1101 (1982).
52. M. Sebaihia, B. W. Wren, P. Mullany, N. F. Fairweather, N. Minton, R. Stabler, N. R. Thomson, A. P. Roberts, A. M. Cerdeo-Tárraga, H. Wang, M. T. Holden, A. Wright, C. Churcher, M. A. Quail, S. Baker, N. Bason, K. Brooks, T. Chillingworth, A. Cronin, P. Davis, L. Dowd, A. Fraser, T. Feltwell, Z. Hance, S. Holroyd, K. Jagels, S. Moule, K. Mungall, C. Price, E. Rabbinowitsch, S. Sharp, M. Simmonds, K. Stevens, L. Unwin, S. Whithead, B. Dupuy, G. Dougan, B. Barrell, J. Parkhill, The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat. Genet. 38, 779-786 (2006).
53. X. Chen, K. Katchar, J. D. Goldsmith, N. Nanthakumar, A. Cheknis, D. N. Gerding, C. P. Kelly, Amouse model of Clostridium difficile-associated disease. Gastroenterology 135, 1984-1992 (2008).
54. S. W. Pawlowski, G. Calabrese, G. L. Kolling, J. Platts-Mills, R. Freire, C. AlcantaraWarren, B. Liu, R. B. Sartor, R. L. Guerrant, Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J. Infect. Dis. 202, 1708-1712 (2010).
55. W. N. Al-Nassir, A. K. Sethi, Y. Li, M. J. Pultz, M. M. Riggs, C. J. Donskey, Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob. Agents Chemother. 52, 2403-2406 (2008).
56. E. C. Oldfield IV, E. C. Oldfield III, D. A. Johnson, Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J. Gastrointest. Pharmacol. Ther. 5, 1-26 (2014).
57. T. J. Louie, M. A. Miller, K. M. Mullane, K. Weiss, A. Lentnek, Y. Golan, S. Gorbach, P. Sears, Y.-K. Shue; OPT-80-003 Clinical Study Group, Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431 (2011).
58. I. Kreimeyer, F. Euler, A. Marckscheffel, H. Tatge, A. Pich, A. Olling, J. Schwarz, I. Just, R. Gerhard, Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A. Naunyn Schmiedeberg's Arch. Pharmacol. 383, 253-262 (2011).
59. G. Yang, B. Zhou, J. Wang, X. He, X. Sun, W. Nie, S. Tzipori, H. Feng, Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol. 8, 192 (2008).
60. S. Bagrodia, S. J. Taylor, C. L. Creasy, J. Chernoff, R. A. Cerione, Identification of a mouse p21Cdc42/Rac activated kinase. J. Biol. Chem. 270, 22731-22737 (1995).
61. J. Tam, G. L. Beilhartz, A. Auger, P. Gupta, A. G. Therien, R. A. Melnyk, Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. Chem. Biol. 22, 175-185 (2015).
62. J. Inglese, D. S. Auld, A. Jadhav, R. L. Johnson, A. Simeonov, A. Yasgar, W. Zheng, C. P. Austin, Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U.S.A. 103, 11473-11478 (2006).
63. V. Brandes, I. Schelle, S. Brinkmann, F. Schulz, J. Schwarz, R. Gerhard, H. Genth, Protection from Clostridium difficile toxin B-catalysed Rac1/Cdc42 glucosylation by tauroursodeoxycholic acid-induced Rac1/Cdc42 phosphorylation. Biol. Chem. 393, 77-84 (2012).
64. R. N. Pruitt, B. Chagot, M. Cover, W. J. Chazin, B. Spiller, D. B. Lacy, Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J. Biol. Chem. 284, 21934-21940 (2009).